BrightPath Biotherapeutics Co., Ltd.
BrightPath Biotherapeutics Co., Ltd. scores highest on Torque (48) and lowest on Price (10). Its PosiPenta is 20.80 out of 100, weaker than most similar companies.
On the Penta Grid this week, BrightPath Biotherapeutics Co., Ltd. is Grid #53 of 53 in the Healthcare sector in Japan, and Grid #1,050 of 1,059 in Japan.
Compared with similar companies in the Healthcare sector in Japan.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| BrightPath Biotherapeutics Co., Ltd. | 20.80 | 10 | 21 | 12 | 48 | 13 |
| SUSMED,Inc. | 33.21 | 28 | 50 | 3 | 57 | 29 |
| Nippon Chemiphar Co., Ltd. | 36.69 | 50 | 13 | 41 | 22 | 58 |
| CellSource Co., Ltd. | 46.66 | 42 | 60 | 20 | 77 | 35 |
| PRISM BioLab Co.,LTD | 23.97 | 13 | 16 | 17 | 53 | 21 |
| Hi-CRATES CO.,LTD. | 68.48 | 80 | 55 | 65 | 83 | 60 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -3.17 |
| P/B ratio | 3.12 |
EEarnings
| Trailing EPS | ₹-7.83 |
| Forward EPS | — |
NNitro
| Price | 24.82 |
| 52-week high | 58.12 |
| 52-week low | 23.61 |
| Fall from 52-week high | 57.3% |
TTorque
| Return on equity (ROE) | -79.25% |
| Debt-to-equity | 0.00 |
AAnchor
| Beta (price swings) | 1.31 |
| Market cap | ₹344 Cr |
| Insider holding | 4.63% |
| Dividend yield | 0.00% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is BrightPath Biotherapeutics Co., Ltd.'s PosiPenta score?
BrightPath Biotherapeutics Co., Ltd.'s PosiPenta is 20.80 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Where does BrightPath Biotherapeutics Co., Ltd. stand on the Penta Grid?
On the Penta Grid this week, BrightPath Biotherapeutics Co., Ltd. is Grid #53 of 53 in the Healthcare sector in Japan, and Grid #1,050 of 1,059 in Japan.
Which PosiPenta pillar is strongest for BrightPath Biotherapeutics Co., Ltd.?
Torque (durability), with a score of 48 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for BrightPath Biotherapeutics Co., Ltd.?
Price (valuation), with a score of 10 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.